Deciphering the cellular landscape of pathological scars

Abstract

Pathological scars (PSs) are characterized by excess dermal collagen deposition and primarily manifest as hypertrophic scars and keloids. The microenvironment of PSs is shaped by a diverse array of cells, collectively forming a profibrotic and proangiogenic niche. Recent advances in high-throughput sequencing have enhanced our understanding of the cellular heterogeneity, transcriptional changes, and intercellular communication within the PS microenvironment. This review comprehensively describes the cellular landscape of PSs, including mesenchymal cells, endothelial cells, epithelial cells, and immune cells. Additionally, we evaluate precision medicine strategies ranging from biomarker-driven diagnostics to targeted biological therapies and innovative drug delivery systems. We aim to provide a mechanistic framework that accelerates the translation of basic experimental research into effective and personalized treatments for pathological scarring.

Keywords

Hypertrophic scar / Keloid / Wound healing / Cellular landscape / Pathological scar

References

[1] Andrews JP, Marttala J, Macarak E, Rosenbloom J, Uitto J. Keloids: the paradigm of skin fibrosis-pathomechanisms and treatment. Matrix Biol 2016; 51:37-46. https://doi.org/10.1016/j.matbio.2016.01.013.

[2] Shan M, Wang Y. Viewing keloids within the immune microenvironment. Am J Transl Res 2022; 14:718-27.

[3] Nyika DT, Khumalo NP, Bayat A. Genetics and epigenetics of keloids. Adv Wound Care (New Rochelle) 2022; 11:192-201. https://doi.org/10.1089/wound.2021.0094.

[4] Zhang T, Wang XF, Wang ZC, Lou D, Fang QQ, Hu YY, et al. Current potential therapeutic strategies targeting the TGF-β/Smad signaling pathway to attenuate keloid and hypertrophic scar formation. Biomed Pharmacother 2020; 129:110287. https://doi.org/10.1016/j.biopha.2020.110287.

[5] Wen J, Li Z, Tan Y, Tey HL, Yu N, Wang X. Endothelial dysfunction in keloid formation and therapeutic insights. J Invest Dermatol 2025; 145:2436-48.https://doi.org/10.1016/j.jid.2025.02.134.

[6] Su Z, Jiao H, Fan J, Liu L, Tian J, Gan C, et al. Warburg effect in keloids: a unique feature different from other types of scars. Burns 2022; 48:176-83. https://doi.org/10.1016/j.burns.2021.03.003.

[7] Xiao K, Wang S, Chen W, Hu Y, Chen Z, Liu P, et al. Identification of novel immune-related signatures for keloid diagnosis and treatment: insights from integrated bulk RNA-seq and scRNA-seq analysis. Hum Genomics 2024; 18:80. https://doi.org/10.1186/s40246-024-00647-z.

[8] Vorstandlechner V, Laggner M, Copic D, Klas K, Direder M, Chen Y, et al. The serine proteases dipeptidyl-peptidase 4 and urokinase are key molecules in human and mouse scar formation. Nat Commun 2021; 12:6242. https://doi.org/10.1038/s41467-021-26495-2.

[9] Gold MH, Nestor MS, Berman B, Goldberg D. Assessing keloid recurrence following surgical excision and radiation. Burns Trauma 2020; 8:tkaa031. https://doi.org/10.1093/burnst/tkaa031.

[10] Ledon JA, Savas J, Franca K, Chacon A, Nouri K. Intralesional treatment for keloids and hypertrophic scars: a review. Dermatologic Surg 2013; 39:1745-57. https://doi.org/10.1111/dsu.12346.

[11] Sun Y, Li Z, Qi X, Wang B, Yu N, Huang J, et al. Laser therapy for treating cleft lip or/and palate scarring-a systematic review and meta-analysis. Lasers Med Sci 2024; 39:160. https://doi.org/10.1007/s10103-024-04082-3.

[12] Mamalis AD, Lev-Tov H, Nguyen DH, Jagdeo JR. Laser and light-based treatment of keloids-a review. J Eur Acad Dermatol Venereol 2014; 28:689-99. https://doi.org/10.1111/jdv.12253.

[13] Dong W, Qiu B, Fan F. Adjuvant radiotherapy for keloids. Aesth Plast Surg 2022; 46:489-99. https://doi.org/10.1007/s00266-021-02442-w.

[14] Peng Q, Lu Y, Huang R, Chen R. Should we do postoperative radiotherapy after keloid excision as soon as possible? A systematic review and meta-analysis. Aesth Plast Surg 2025; 49:4671-82. https://doi.org/10.1007/s00266-025-04869-x.

[15] Deng CC, Hu YF, Zhu DH, Cheng Q, Gu JJ, Feng QL, et al. Single-cell RNA-seq reveals fibroblast heterogeneity and increased mesenchymal fibroblasts in human fibrotic skin diseases. Nat Commun 2021; 12:3709. https://doi.org/10.1038/s41467-021-24110-y.

[16] Direder M, Weiss T, Copic D, Vorstandlechner V, Laggner M, Pfisterer K, et al. Schwann cells contribute to keloid formation. Matrix Biol 2022; 108:55-76. https://doi.org/10.1016/j.matbio.2022.03.001.

[17] Cheong JC, Van Deursen S, Amador D, Hiner S, Woappi Y. 4D multimodal wound healing atlas reveals organ-level controls of repair phase transitions. bioRxiv. 2026.

[18] Yin Z, Huang C, Guo Y, Xu W, Zheng Y, Cao Y. Learning mechanical inhomogeneity of keloid scars in vivo with shear wave elastography based on physics-informed neural networks. Acta Biomater 2025; 208:375-85. https://doi.org/10.1016/j.actbio.2025.10.056.

[19] Sun L, Zhang X, Wu S, Liu Y, Guerrero-Juarez CF, Liu W, et al. Dynamic interplay between IL-1 and WNT pathways in regulating dermal adipocyte lineage cells during skin development and wound regeneration. Cell Rep 2023; 42:112647. https://doi.org/10.1016/j.celrep.2023.112647.

[20] Shim J, Oh SJ, Yeo E, Park JH, Bae JH, Kim SH, et al. Integrated analysis of single-cell and spatial transcriptomics in keloids: highlights on fibrovascular interactions in keloid pathogenesis. J Invest Dermatol 2022; 142:2128-39.e11. https://doi.org/10.1016/j.jid.2022.01.017.

[21] Liao Z, Zheng Y, Zhang M, Li X, Wang J, Xu H. Dynamic single-cell transcriptomic reveals the cellular heterogeneity and a novel fibroblast subpopulation in laryngotracheal stenosis. Biol Direct 2025; 20:40. https://doi.org/10.1186/s13062-025-00639-6.

[22] Liu X, Chen W, Zeng Q, Ma B, Li Z, Meng T, et al. Single-cell RNA-sequencing reveals lineage-specific regulatory changes of fibroblasts and vascular endothelial cells in keloids. J Invest Dermatol 2022; 142:124-35.e11. https://doi.org/10.1016/j.jid.2021.06.010.

[23] Xu H, Zhu Z, Hu J, Sun J, Wo Y, Wang X, et al. Downregulated cytotoxic CD8(+) T-cell identifies with the NKG2A-soluble HLA-E axis as a predictive biomarker and potential therapeutic target in keloids. Cell Mol Immunol 2022; 19:527-39. https://doi.org/10.1038/s41423-021-00834-1.

[24] Yeo E, Shim J, Oh SJ, Choi Y, Noh H, Kim H, et al. Revisiting roles of mast cells and neural cells in keloid: exploring their connection to disease activity. Front Immunol 2024; 15:1339336. https://doi.org/10.3389/fimmu.2024.1339336.

[25] Cheng X, Gao Z, Shan S, Shen H, Zheng H, Jin L, et al. Single cell transcriptomics reveals the cellular heterogeneity of keloids and the mechanism of their aggressiveness. Commun Biol 2024; 7:1647. https://doi.org/10.1038/s42003-024-07311-1.

[26] Oh S, Yeo E, Shim J, Noh H, Park J, Lee KT, et al. Revealing the pathogenesis of keloids based on the status: active vs inactive. Exp Dermatol 2024; 33:e15088. https://doi.org/10.1111/exd.15088.

[27] Shi X, Xia X, Xiao Y, Zhang Y, Gong Y, Chen Y, et al. Increased melanin induces aberrant keratinocyte-melanocyte-basal-fibroblast cell communication and fibrogenesis by inducing iron overload and ferroptosis resistance in keloids. Cell Commun Signal 2025; 23:141. https://doi.org/10.1186/s12964-025-02116-z.

[28] Akita S, Ikehara S, Kiuchi M, Kokubo K, Azuma K, Ohki S, et al. Increased expression of the PIEZO2 mechanoreceptor in fibroblasts and endothelial cells within the lymphatic and vascular vessels of keloids. J Pathol 2025; 267:105-19. https://doi.org/10.1002/path.6455.

[29] Zhao S, Xie J, Zhang Q, Ni T, Lin J, Gao W, et al. New antifibrotic strategies for keloids: insights from single-cell multi-omics. Cell Prolif 2025; 58:e13818. https://doi.org/10.1111/cpr.13818.

[30] Hong YK, Hwang DY, Yang CC, Cheng SM, Chen PC, Aala WJ, et al. Profibrotic subsets of SPP1(+) macrophages and POSTN(+) fibroblasts contribute to fibrotic scarring in acne keloidalis. J Invest Dermatol 2024; 144:1491-504.e10. https://doi.org/10.1016/j.jid.2023.12.014.

[31] Dou S, Zhang F, He Y, Du P, Deng Y, Shao M, et al. PRRX1 is a key regulator in the phenotypic transition between human normal dermal and keloid fibroblasts. J Dermatol Sci 2025; 119:28-39. https://doi.org/10.1016/j.jdermsci.2025.05.002.

[32] Rao A, Barkley D, França GS, Yanai I. Exploring tissue architecture using spatial transcriptomics. Nature. 2021; 596:211-20.

[33] Chen KH, Boettiger AN, Moffitt JR, Wang S, Zhuang X. RNA imaging. Spatially resolved, highly multiplexed RNA profiling in single cells. Science. 2015; 348:aaa6090.

[34] Ståhl PL, Salmén F, Vickovic S, Lundmark A, Navarro JF, Magnusson J, et al. Visualization and analysis of gene expression in tissue sections by spatial transcriptomics. Science. 2016; 353:78-82.

[35] Li Y, Ju S, Li X, Li W, Zhou S, Wang G, et al. Characterization of the microenvironment of diabetic foot ulcers and potential drug identification based on scRNA-seq. Front Endocrinol (Lausanne) 2022; 13:997880. https://doi.org/10.3389/fendo.2022.1082799.

[36] Li K, Samiei S, Pikulska D, Foecking S, Kuppe C. Advancing cardiovascular research with single-cell and spatial transcriptomics. Circ Res 2026; 138:e325795. https://doi.org/10.1161/CIRCRESAHA.125.325795.

[37] Morioka N, Ganier C, Watt FM. Fetal fibroblast heterogeneity defines dermal architecture during human embryonic skin development. J Invest Dermatol 2025; 145:1081-91.e7. https://doi.org/10.1016/j.jid.2024.12.027.

[38] Jones CFE, Di Cio S, Connelly JT, Gautrot JE. Design of an integrated microvascularized human skin-on-a-chip tissue equivalent model. Front Bioeng Biotechnol 2022; 10:915702. https://doi.org/10.3389/fbioe.2022.915702.

[39] Zhao Y, Wu S, Cai Y, Yang H, Dong X, Yang B, et al. Integration of finite element simulations with 3D printing technology for personalized chitin/PLA microneedle-based drug delivery systems in thoracic keloid treatment. Int J Biol Macromol 2025; 315:144487. https://doi.org/10.1016/j.ijbiomac.2025.144487.

[40] Guo Z, Yu Q, Huang W, Huang F, Chen X, Wei C. Discovering and validating cuproptosis-associated marker genes for accurate keloid diagnosis through multiple machine learning models. Clin Cosmet Investig Dermatol 2024; 17:287-300. https://doi.org/10.2147/CCID.S440231.

[41] Wen Z, Ablimit A. Comprehensive analysis of scRNA-Seq and bulk RNA-Seq reveals ubiquitin promotes pulmonary fibrosis in chronic pulmonary diseases. Sci Rep 2024; 14:21195. https://doi.org/10.1038/s41598-024-70659-1.

[42] Wu Y, Tang F. scExtract: leveraging large language models for fully automated single-cell RNA-seq data annotation and prior-informed multi-dataset integration. Genome Biol 2025; 26:174. https://doi.org/10.1186/s13059-025-03639-x.

[43] Feng C, Shan M, Xia Y, Zheng Z, He K, Wei Y, et al. Single-cell RNA sequencing reveals distinct immunology profiles in human keloid. Front Immunol 2022; 13:940645. https://doi.org/10.3389/fimmu.2022.940645.

[44] Tai Y, Woods EL, Dally J, Kong D, Steadman R, Moseley R, et al. Myofibroblasts: function, formation, and scope of molecular therapies for skin fibrosis. Biomolecules 2021; 11:1095. https://doi.org/10.3390/biom11081095.

[45] Darby IA, Laverdet B, Bonté F, Desmoulière A. Fibroblasts and myofibroblasts in wound healing. Clin Cosmet Investig Dermatol 2014; 7:301-11. https://doi.org/10.2147/CCID.S50046.

[46] He J, Fang B, Shan S, Xie Y, Wang C, Zhang Y, et al. Mechanical stretch promotes hypertrophic scar formation through mechanically activated cation channel Piezo1. Cell Death Dis 2021; 12:226. https://doi.org/10.1038/s41419-021-03481-6.

[47] Huang C, Liu L, You Z, Wang B, Du Y, Ogawa R. Keloid progression: a stiffness gap hypothesis. Int Wound J 2017; 14:764-71. https://doi.org/10.1111/iwj.12693.

[48] Cao N, Xiong X, Liu S, Kong W, Zhao Y. Keloids as a spectrum of auto-inflammatory fibrotic disorders: beyond the conventional wound-healing paradigm. Clin Cosmet Investig Dermatol 2025; 18:3719-33. https://doi.org/10.2147/CCID.S571711.

[49] Ogawa R. Keloid and hypertrophic scars are the result of chronic inflammation in the reticular dermis. Int J Mol Sci 2017; 18:606. https://doi.org/10.3390/ijms18030606.

[50] Hahn JM, McFarland KL, Combs KA, Powell HM, Supp DM. Myofibroblasts are not characteristic features of keloid lesions. Plast Reconstr Surg Glob Open 2022; 10:e4680. https://doi.org/10.1097/GOX.0000000000004680.

[51] Chancheewa B, Asawanonda P, Noppakun N, Kumtornrut C. Myofibroblasts, B cells, and mast cells in different types of long-standing acne scars. Skin Appendage Disord 2022; 8:469-75. https://doi.org/10.1159/000524566.

[52] Guo L, Mi JW, Zhang HC, Gao J, Zhang S, Li LX, et al. Endothelial-mesenchymal transition as a novel mechanism for generating myofibroblasts during wound healing and scarring. J Cosmet Dermatol 2023; 22:661-8. https://doi.org/10.1111/jocd.15466.

[53] Haensel D, Dai X. Epithelial-to-mesenchymal transition in cutaneous wound healing: where we are and where we are heading. Dev Dyn 2018; 247:473-80. https://doi.org/10.1002/dvdy.24561.

[54] Hinz B, Phan SH, Thannickal VJ, Prunotto M, Desmoulière A, Varga J, et al. Recent developments in myofibroblast biology: paradigms for connective tissue remodeling. Am J Pathol 2012; 180:1340-55. https://doi.org/10.1016/j.ajpath.2012.02.004.

[55] Lichtman MK, Otero-Vinas M, Falanga V . Transforming growth factor beta (TGF-β) isoforms in wound healing and fibrosis. Wound Repair Regen 2016; 24:215-22. https://doi.org/10.1111/wrr.12398.

[56] Su Z, Fan J, Liu L, Jiao H, Tian J, Gan C, et al. Inhibiting Warburg effect can suppress the biological activity and secretion function of keloid fibroblasts. Aesth Plast Surg 2022; 46:1964-72. https://doi.org/10.1007/s00266-022-02899-3.

[57] Wang P, Wang Q, Yang X, An Y, Wang J, Nie F, et al. Targeting the glycolytic enzyme PGK1 to inhibit the Warburg effect: a new strategy for keloid therapy. Plast Reconstr Surg 2023; 151:970e-80. https://doi.org/10.1097/PRS.0000000000010137.

[58] Vinaik R, Barayan D, Auger C, Abdullahi A, Jeschke MG. Regulation of glycolysis and the Warburg effect in wound healing. JCI Insight 2020; 5:e138949. https://doi.org/10.1172/jci.insight.138949.

[59] Huo P, Wang S, Li Z, Jin Z. ACSS3 protein macromolecule regulates glycolysis in keloid through Wnt/β-catenin signaling pathway: bioinformatics, machine learning, and experimental validation. Cell Signal 2025; 135:112056. https://doi.org/10.1016/j.cellsig.2025.112056.

[60] Liu Y, Yang Z, Lin N, Liu Y, Chen H. Highly expressed VGLL3 in keloid fibroblasts promotes glycolysis and collagen production via the activation of Wnt/β-catenin signaling. Cell Signal 2025; 127:111604. https://doi.org/10.1016/j.cellsig.2025.111604.

[61] Oishi M, Shinjo K, Takanari K, Muraoka A, Suzuki MM, Kanbe M, et al. Exclusive expression of KANK4 promotes myofibroblast mobility in keloid tissues. Sci Rep 2024; 14:8725. https://doi.org/10.1038/s41598-024-59293-z.

[62] Yang E, Xu R, Zhang H, Xia W, Huang X, Zan T. Deciphering pain and pruritus in keloids from the perspective of neurological dysfunction: where are we now? Biomedicines 2025; 13:663. https://doi.org/10.3390/biomedicines13030663.

[63] Tey HL, Maddison B, Wang H, Ishiju Y, McMichael A, Marks M, et al. Cutaneous innervation and itch in keloids. Acta Derm Venereol 2012; 92:529-31. https://doi.org/10.2340/00015555-1336.

[64] Gomez-Sanchez JA, Pilch KS, van der Lans M, Fazal SV, Benito C, Wagstaff LJ, et al. After nerve injury, lineage tracing shows that myelin and Remak Schwann cells elongate extensively and branch to form repair Schwann cells, which shorten radically on remyelination. J Neurosci 2017; 37:9086-99. https://doi.org/10.1523/JNEUROSCI.1453-17.2017.

[65] Jessen KR, Mirsky R. The repair Schwann cell and its function in regenerating nerves. J Physiol 2016; 594:3521-31. https://doi.org/10.1113/JP270874.

[66] Direder M, Wielscher M, Weiss T, Laggner M, Copic D, Klas K, et al. The transcriptional profile of keloidal Schwann cells. Exp Mol Med 2022; 54:1886-900. https://doi.org/10.1038/s12276-022-00874-1.

[67] Gong T, Wang Y, Dong S, Ma X, Du D, Zou C, et al. Single-cell RNA-seq reveals the communications between extracellular matrix-related components and Schwann cells contributing to the earlobe keloid formation. Front Med (Lausanne) 2022; 9:1000324. https://doi.org/10.3389/fmed.2022.1000324.

[68] Bi M, Sun P, Li D, Dong Z, Chen Z. Intralesional injection of botulinum toxin type a compared with intralesional injection of corticosteroid for the treatment of hypertrophic scar and keloid: a systematic review and meta-analysis. Med Sci Monit 2019; 25:2950-8. https://doi.org/10.12659/MSM.916305.

[69] Moon JH, Kwak SS, Park G, Jung HY, Yoon BS, Park J, et al. Isolation and characterization of multipotent human keloid-derived mesenchymal-like stem cells. Stem Cells Dev 2008; 17:713-24. https://doi.org/10.1089/scd.2007.0210.

[70] Zhang Q, Yamaza T, Kelly AP, Shi S, Wang S, Brown J, et al. Tumor-like stem cells derived from human keloid are governed by the inflammatory niche driven by IL-17/IL-6 axis. PLoS One 2009; 4:e7798. https://doi.org/10.1371/journal.pone.0007798.

[71] Hahn JM, McFarland KL, Combs KA, Supp DM. Partial epithelial-mesenchymal transition in keloid scars: regulation of keloid keratinocyte gene expression by transforming growth factor-β1. Burns Trauma 2016; 4:30. https://doi.org/10.1186/s41038-016-0055-7.

[72] Zhang YX, Liu LP, Li M, Huang JL, Xu H, Chen XD, et al. Development of individualized induced pluripotent stem cells from fibroblasts of keloid lesions in patients. Transplant Proc 2018; 50:2868-71. https://doi.org/10.1016/j.transproceed.2018.04.008.

[73] Xia Y, Wang Y, Shan M, Hao Y, Liang Z. Decoding the molecular landscape of keloids: new insights from single-cell transcriptomics. Burns Trauma 2023; 11:tkad017. https://doi.org/10.1093/burnst/tkad017.

[74] Tan Y, Zhang M, Kong Y, Zhang F, Wang Y, Huang Y, et al. Fibroblasts and endothelial cells interplay drives hypertrophic scar formation: insights from in vitro and in vivo models. Bioeng Transl Med 2024; 9:e10630. https://doi.org/10.1002/btm2.10630.

[75] Kiya K, Kubo T, Kawai K, Matsuzaki S, Maeda D, Fujiwara T, et al. Endothelial cell-derived endothelin-1 is involved in abnormal scar formation by dermal fibroblasts through RhoA/rho-kinase pathway. Exp Dermatol 2017; 26:705-12. https://doi.org/10.1111/exd.13264.

[76] Kurokawa N, Ueda K, Tsuji M. Study of microvascular structure in keloid and hypertrophic scars: density of microvessels and the efficacy of three-dimensional vascular imaging. J Plast Surg Hand Surg 2010; 44:272-7. https://doi.org/10.3109/2000656X.2010.532923.

[77] Touchi R, Ueda K, Kurokawa N, Tsuji M. Central regions of keloids are severely ischaemic. J Plast Reconstr Aesthet Surg 2016; 69:e35-41. https://doi.org/10.1016/j.bjps.2015.11.006.

[78] Wang XQ, Song F, Liu YK. Hypertrophic scar regression is linked to the occurrence of endothelial dysfunction. PLoS One 2017; 12:e0176681. https://doi.org/10.1371/journal.pone.0178198.

[79] Eura S, Nakao J, Iimura T, Ichinose S, Kaku C, Dohi T, et al. Hemodynamics and vascular histology of keloid tissues and anatomy of nearby blood vessels. Plast Reconstr Surg Glob Open 2022; 10:e4374. https://doi.org/10.1097/GOX.0000000000004374.

[80] Makarenko VV, Usatyuk PV, Yuan G, Lee MM, Nanduri J, Natarajan V, et al. Intermittent hypoxia-induced endothelial barrier dysfunction requires ROS-dependent MAP kinase activation. Am J Physiol Cell Physiol 2014; 306:C745-52. https://doi.org/10.1152/ajpcell.00313.2013.

[81] Lei R, Li J, Liu F, Li W, Zhang S, Wang Y, et al. HIF-1α promotes the keloid development through the activation of TGF-β/Smad and TLR4/MyD88/NF-κB pathways. Cell Cycle 2019; 18:3239-50. https://doi.org/10.1080/15384101.2019.1670508.

[82] Kang Y, Roh MR, Rajadurai S, Rajadurai A, Kumar R, Njauw CN, et al. Hypoxia and HIF-1α regulate collagen production in keloids. J Invest Dermatol 2020; 140:2157-65. https://doi.org/10.1016/j.jid.2020.01.036.

[83] Qiu ZK, Zhang MZ, Zhang WC, Li ZJ, Si LB, Long X, et al. Role of HIF-1α in pathogenic mechanisms of keloids. J Cosmet Dermatol 2023; 22:1436-48. https://doi.org/10.1111/jocd.15601.

[84] Teng Y, Hao Y, Liu H, Shan M, Chen Q, Song K, et al. Histology and vascular architecture study of keloid tissue to outline the possible terminology of keloid skin flaps. Aesth Plast Surg 2022; 46:985-94. https://doi.org/10.1007/s00266-022-02775-0.

[85] Chen C, Zhang M, Yu N, Zhang W, Long X, Wang Y, et al. Heterogeneous features of keloids assessed by laser speckle contrast imaging: a cross-sectional study. Lasers Surg Med 2021; 53:865-71. https://doi.org/10.1002/lsm.23331.

[86] Yang Y, Liu L, Yang R, Ding X, Li Y, Liu H, et al. Blood perfusion in hypertrophic scars and keloids studied by laser speckle contrast imaging. Skin Res Technol 2021; 27:789-96. https://doi.org/10.1111/srt.13020.

[87] Medici D, Kalluri R. Endothelial-mesenchymal transition and its contribution to the emergence of stem cell phenotype. Semin Cancer Biol 2012; 22:379-84. https://doi.org/10.1016/j.semcancer.2012.04.004.

[88] Lee WJ, Park JH, Shin JU, Noh H, Lew DH, Yang WI, et al. Endothelial-to-mesenchymal transition induced by Wnt 3a in keloid pathogenesis. Wound Repair Regen 2015; 23:435-42. https://doi.org/10.1111/wrr.12300.

[89] Rosa I, Romano E, Fioretto BS, El Aoufy K, Bellando-Randone S, Matucci-Cerinic M, et al. Lymphatic endothelial-to-myofibroblast transition: a potential new mechanism underlying skin fibrosis in systemic sclerosis. Cells 2023; 12:2195. https://doi.org/10.3390/cells12172195.

[90] Yang S, Sun Y, Geng Z, Ma K, Sun X, Fu X. Abnormalities in the basement membrane structure promote basal keratinocytes in the epidermis of hypertrophic scars to adopt a proliferative phenotype. Int J Mol Med 2016; 37:1263-73. https://doi.org/10.3892/ijmm.2016.2519.

[91] Li B, Gao C, Diao JS, Wang DL, Chu FF, Li Y, et al. Aberrant notch signalling contributes to hypertrophic scar formation by modulating the phenotype of keratinocytes. Exp Dermatol 2016; 25:137-42. https://doi.org/10.1111/exd.12897.

[92] Lee YI, Shim JE, Kim J, Lee WJ, Kim JW, Nam KH, et al. WNT5A drives interleukin-6-dependent epithelial-mesenchymal transition via the JAK/STAT pathway in keloid pathogenesis. Burns Trauma 2022; 10:tkac023. https://doi.org/10.1093/burnst/tkac023.

[93] Yang S, Zhao J, Huang S, Shu B, Yang R, Chen L, et al. Reduced hydration-induced decreased caveolin-1 expression causes epithelial-to-mesenchymal transition. Am J Transl Res 2020; 12:8067-83.

[94] Zhao J, Yu J, Xu Y, Chen L, Zhou F, Zhai Q, et al. Epidermal HMGB1 activates dermal fibroblasts and causes hypertrophic scar formation in reduced hydration. J Invest Dermatol 2018; 138:2322-32. https://doi.org/10.1016/j.jid.2018.04.036.

[95] Zhao J, Zhong A, Friedrich EE, Jia S, Xie P, Galiano RD, et al. S100A12 induced in the epidermis by reduced hydration activates dermal fibroblasts and causes dermal fibrosis. J Invest Dermatol 2017; 137:650-9. https://doi.org/10.1016/j.jid.2016.10.040.

[96] Sun Y, Chen Z, Zhang M, Zhang H, Li T, Li Y, et al. FOSL1-mediated super-enhancer facilitates pathological scarring. Cell Rep 2026; 45:117667. https://doi.org/10.1016/j.celrep.2026.117667.

[97] Canady J, Arndt S, Karrer S, Bosserhoff AK. Increased KGF expression promotes fibroblast activation in a double paracrine manner resulting in cutaneous fibrosis. J Invest Dermatol 2013; 133:647-57. https://doi.org/10.1038/jid.2012.389.

[98] Cui HS, Joo SY, Lee SY, Cho YS, Kim DH, Seo CH. Effect of hypertrophic scar fibroblast-derived exosomes on keratinocytes of normal human skin. Int J Mol Sci 2023; 24:6132. https://doi.org/10.3390/ijms24076132.

[99] Gao FL, Jin R, Zhang L, Zhang YG. The contribution of melanocytes to pathological scar formation during wound healing. Int J Clin Exp Med 2013; 6:609-13.

[100] Shen Z, Shao J, Sun J, Xu J. Exosomes released by melanocytes modulate fibroblasts to promote keloid formation: a pilot study. J Zhejiang Univ Sci B 2022; 23:699-704. https://doi.org/10.1631/jzus.B2200036.

[101] Zhou B, Gao Z, Liu W, Wu X, Wang W. Important role of mechanical microenvironment on macrophage dysfunction during keloid pathogenesis. Exp Dermatol 2022; 31:375-80. https://doi.org/10.1111/exd.14473.

[102] Shapouri-Moghaddam A, Mohammadian S, Vazini H, Taghadosi M, Esmaeili SA, Mardani F, et al. Macrophage plasticity, polarization, and function in health and disease. J Cell Physiol 2018; 233:6425-40. https://doi.org/10.1002/jcp.26429.

[103] Xu X, Gu S, Huang X, Ren J, Gu Y, Wei C, et al. The role of macrophages in the formation of hypertrophic scars and keloids. Burns Trauma 2020; 8:tkaa006. https://doi.org/10.1093/burnst/tkaa006.

[104] Chao H, Zheng L, Hsu P, He J, Wu R, Xu S, et al. IL-13RA2 downregulation in fibroblasts promotes keloid fibrosis via JAK/STAT6 activation. JCI Insight 2023; 8:e157091. https://doi.org/10.1172/jci.insight.157091.

[105] Butzelaar L, Schooneman DP, Soykan EA, Talhout W, Ulrich MM, van den Broek LJ, et al. Inhibited early immunologic response is associated with hypertrophic scarring. Exp Dermatol 2016; 25:797-804. https://doi.org/10.1111/exd.13100.

[106] Williams H, Suda S, Dervish S, Yap YT, Holland AJA, Medbury HJ. Monocyte M1/M2 profile is altered in paediatric burn patients with hypertrophic scarring. Wound Repair Regen 2021; 29:996-1005. https://doi.org/10.1111/wrr.12960.

[107] Chen L, Wang J, Li S, Yu Z, Liu B, Song B, et al. The clinical dynamic changes of macrophage phenotype and function in different stages of human wound healing and hypertrophic scar formation. Int Wound J 2019; 16:360-9. https://doi.org/10.1111/iwj.13041.

[108] Limandjaja GC, Waaijman T, Roffel S, Niessen FB, Gibbs S. Monocytes co-cultured with reconstructed keloid and normal skin models skew towards M2 macrophage phenotype. Arch Dermatol Res 2019; 311:615-27. https://doi.org/10.1007/s00403-019-01942-9.

[109] Nangole FW, Agak GW. Keloid pathophysiology: fibroblast or inflammatory disorders? JPRAS Open 2019; 22:44-54. https://doi.org/10.1016/j.jpra.2019.09.004.

[110] Seoudy WM, Mohy El Dien SM, Abdel Reheem TA, Elfangary MM, Erfan MA. Macrophages of the M1 and M2 types play a role in keloids pathogenesis. Int Wound J 2023; 20:38-45. https://doi.org/10.1111/iwj.13834.

[111] Diaz A, Tan K, He H, Xu H, Cueto I, Pavel AB, et al. Keloid lesions show increased IL-4/IL-13 signaling and respond to Th2-targeting dupilumab therapy. J Eur Acad Dermatol Venereol 2020; 34:e161-4. https://doi.org/10.1111/jdv.16097.

[112] Liu J, Huang Y, Gong Y, Liu Q, Lin J, Liu J, et al. CTHRC1+ fibroblasts are stimulated by macrophage-secreted SPP1 to induce excessive collagen deposition in keloids. Clin Transl Med 2022; 12:e1115. https://doi.org/10.1002/ctm2.1115.

[113] Jin Q, Gui L, Niu F, Yu B, Lauda N, Liu J, et al. Macrophages in keloid are potent at promoting the differentiation and function of regulatory T cells. Exp Cell Res 2018; 362:472-6. https://doi.org/10.1016/j.yexcr.2017.12.011.

[114] Boyce DE, Ciampolini J, Ruge F, Murison MS, Harding KG. Inflammatory-cell subpopulations in keloid scars. Br J Plast Surg 2001; 54:511-6. https://doi.org/10.1054/bjps.2001.3638.

[115] Castagnoli C, Trombotto C, Ondei S, Stella M, Calcagni M, Magliacani G, et al. Characterization of T-cell subsets infiltrating post-burn hypertrophic scar tissues. Burns 1997; 23:565-72. https://doi.org/10.1016/S0305-4179(97)00070-3.

[116] Nguyen JK, Austin E, Huang A, Mamalis A, Jagdeo J. The IL-4/IL-13 axis in skin fibrosis and scarring: mechanistic concepts and therapeutic targets. Arch Dermatol Res 2020; 312:81-92. https://doi.org/10.1007/s00403-019-01972-3.

[117] Wu J, Del Duca E, Espino M, Gontzes A, Cueto I, Zhang N, et al. RNA sequencing keloid transcriptome associates keloids with Th2, Th1, Th17/Th22, and JAK3-skewing. Front Immunol 2020; 11:597741. https://doi.org/10.3389/fimmu.2020.597741.

[118] Tredget EE, Yang L, Delehanty M, Shankowsky H, Scott PG. Polarized Th2 cytokine production in patients with hypertrophic scar following thermal injury. J Interf Cytokine Res 2006; 26:179-89. https://doi.org/10.1089/jir.2006.26.179.

[119] Chen B, Li H, Xia W. The role of Th1/Th2 cell chemokine expression in hypertrophic scar. Int Wound J 2020; 17:197-205. https://doi.org/10.1111/iwj.13257.

[120] Lee SY, Kim EK, Seo HB, Choi JW, Yoo JH, Jung KA, et al. IL-17 induced stromal cell-derived factor-1 and profibrotic factor in keloid-derived skin fibroblasts via the STAT3 pathway. Inflammation 2020; 43:664-72. https://doi.org/10.1007/s10753-019-01148-1.

[121] Chen Z, Zhou L, Won T, Gao Z, Wu X, Lu L. Characterization of CD45RO(+) memory T lymphocytes in keloid disease. Br J Dermatol 2018; 178:940-50. https://doi.org/10.1111/bjd.16173.

[122] Chen Y, Jin Q, Fu X, Qiao J, Niu F. Connection between T regulatory cell enrichment and collagen deposition in keloid. Exp Cell Res 2019; 383:111549. https://doi.org/10.1016/j.yexcr.2019.111549.

[123] Anderson JB, Harrant AB, Navarro-Alvarez N, Wang Z, van Bokhoven A, High W, et al. 4371 the role of B cells in keloid formation. J Clin Transl Sci 2020; 4:18-9. https://doi.org/10.1017/cts.2020.97.

[124] Jiao H, Fan J, Cai J, Pan B, Yan L, Dong P, et al. Analysis of characteristics similar to autoimmune disease in keloid patients. Aesth Plast Surg 2015; 39:818-25. https://doi.org/10.1007/s00266-015-0542-4.

[125] Cai H, Liu X, Liu D, Liu B. GEO data mining identifies potential immune-related genes in hypertrophic scar and verities in a rabbit model. Heliyon 2023; 9:e17266. https://doi.org/10.1016/j.heliyon.2023.e17266.

[126] Zhang X, Wu X, Li D. The communication from immune cells to the fibroblasts in keloids: implications for immunotherapy. Int J Mol Sci 2023; 24:15475. https://doi.org/10.3390/ijms242015475.

[127] Min MS, Mazori DR, Lee MS, Merola JF, Vleugels RA, Cobos G, et al. Successful treatment of keloids and hypertrophic scars with systemic and intralesional dupilumab. J Drugs Dermatol 2023; 22:1220-2. https://doi.org/10.36849/JDD.6385.

[128] Tirgan MH, Uitto J. Lack of efficacy of dupilumab in the treatment of keloid disorder. J Eur Acad Dermatol Venereol 2022; 36:e120-2. https://doi.org/10.1111/jdv.17669.

[129] Luk K, Fakhoury J, Ozog D. Nonresponse and progression of diffuse keloids to dupilumab therapy. J Drugs Dermatol 2022; 21:197-9. https://doi.org/10.36849/JDD.6252.

[130] Kritas SK, Saggini A, Cerulli G, Caraffa A, Antinolfi P, Pantalone A, et al. Neuropeptide NGF mediates neuro-immune response and inflammation through mast cell activation. J Biol Regul Homeost Agents 2014; 28:177-81.

[131] Cohen AJ, Nikbakht N, Uitto J. Keloid disorder: genetic basis, gene expression profiles, and immunological modulation of the fibrotic processes in the skin. Cold Spring Harb Perspect Biol 2023; 15:a041245. https://doi.org/10.1101/cshperspect.a041245.

[132] Choi YH, Kim KM, Kim HO, Jang YC, Kwak IS. Clinical and histological correlation in post-burn hypertrophic scar for pain and itching sensation. Ann Dermatol 2013; 25:428-33. https://doi.org/10.5021/ad.2013.25.4.428.

[133] Bagabir R, Byers RJ, Chaudhry IH, Müller W, Paus R, Bayat A. Site-specific immunophenotyping of keloid disease demonstrates immune upregulation and the presence of lymphoid aggregates. Br J Dermatol 2012; 167:1053-66. https://doi.org/10.1111/j.1365-2133.2012.11190.x.

[134] Dong X, Zhang C, Ma S, Wen H. Mast cell chymase in keloid induces profibrotic response via transforming growth factor-β1/Smad activation in keloid fibroblasts. Int J Clin Exp Pathol 2014; 7:3596-607.

[135] Nakajima Y, Aramaki N, Takeuchi N, Yamanishi A, Kumagai Y, Okabe K, et al. Mast cells are activated in the giant earlobe keloids: a case series. Int J Mol Sci 2022; 23:10410. https://doi.org/10.3390/ijms231810410.

[136] Chen H, Xu Y, Yang G, Zhang Q, Huang X, Yu L, et al. Mast cell chymase promotes hypertrophic scar fibroblast proliferation and collagen synthesis by activating TGF-β1/Smads signaling pathway. Exp Ther Med 2017; 14:4438-42. https://doi.org/10.3892/etm.2017.5082.

[137] Algermissen B, Hermes B, Feldmann-Boeddeker I, Bauer F, Henz BM. Mast cell chymase and tryptase during tissue turnover: analysis on in vitro mitogenesis of fibroblasts and keratinocytes and alterations in cutaneous scars. Exp Dermatol 1999; 8:193-8. https://doi.org/10.1111/j.1600-0625.1999.tb00370.x.

[138] Tiberio L, Del Prete A, Schioppa T, Sozio F, Bosisio D, Sozzani S. Chemokine and chemotactic signals in dendritic cell migration. Cell Mol Immunol 2018; 15:346-52. https://doi.org/10.1038/s41423-018-0005-3.

[139] Worbs T, Hammerschmidt SI, Förster R. Dendritic cell migration in health and disease. Nat Rev Immunol 2017; 17:30-48. https://doi.org/10.1038/nri.2016.116.

[140] Onodera M, Ueno M, Ito O, Suzuki S, Igawa HH, Sakamoto H. Factor XIIIa-positive dermal dendritic cells in keloids and hypertrophic and mature scars. Pathol Int 2007; 57:337-42. https://doi.org/10.1111/j.1440-1827.2007.02105.x.

[141] Cracco C, Stella M, Teich Alasia S, Filogamo G. Comparative study of Langerhans cells in normal and pathological human scars II. Hypertrophic scars. Eur J Histochem 1992; 36:53-65.

[142] Björkström NK, Ljunggren HG, Michaëlsson J. Emerging insights into natural killer cells in human peripheral tissues. Nat Rev Immunol 2016; 16:310-20. https://doi.org/10.1038/nri.2016.34.

[143] Wang H, Zhou Z, Liu Y, Wang P, Chen L, Qi S, et al. Identification and validation of HOXD3 and UNC5C as molecular signatures in keloid based on weighted gene co-expression network analysis. Genomics 2022; 114:110403. https://doi.org/10.1016/j.ygeno.2022.110403.

[144] Uzhachenko RV, Shanker A. CD8(+) T lymphocyte and NK cell network: circuitry in the cytotoxic domain of immunity. Front Immunol 2019; 10:1906. https://doi.org/10.3389/fimmu.2019.01906.

[145] Pallmer K, Oxenius A. Recognition and regulation of T cells by NK cells. Front Immunol 2016; 7:251. https://doi.org/10.3389/fimmu.2016.00251.

[146] Wang J, Du J, Song Y, Tan X, Wu J, Wang T, et al. CILP1 interacting with YBX1 promotes hypertrophic scar formation by suppressing PPARs transcription. Cell Death Dis 2025; 16:371.

[147] Wang J, Song Y, Tan X, Wang T, Shi Y, Xu X, et al. Targeting PIM1 by Bruceine D attenuates skin fibrosis via myofibroblast ferroptosis. Redox Biol 2025; 82:103619. https://doi.org/10.1016/j.redox.2025.103619.

[148] Levin AM, Okifo O, Buhl K, Ouchi T, Parker B, Tan J, et al. Higher expression of mir-31-5p is associated with reduced risk of head and neck keloid recurrence following surgical resection. Laryngoscope Investig Otolaryngol 2024; 9:e70040. https://doi.org/10.1002/lio2.70040.

[149] Wang J, Yu N, Wang G, Wang R, Li L, Jiang Y, et al. 68 Ga-FAPI-04 PET/CT in assessment of fibroblast activation in keloids: a prospective pilot study. Clin Nucl Med 2024; 49:16-22. https://doi.org/10.1097/RLU.0000000000004913.

[150] Almet AA, Liu Y, Nie Q, Plikus MV. Integrated single-cell analysis reveals spatially and temporally dynamic heterogeneity in fibroblast states during wound healing. J Invest Dermatol 2025; 145:645-59.e25. https://doi.org/10.1016/j.jid.2024.06.1281.

[151] Unahabhokha T, Sucontphunt A, Nimmannit U, Chanvorachote P, Yongsanguanchai N, Pongrakhananon V. Molecular signalings in keloid disease and current therapeutic approaches from natural based compounds. Pharm Biol 2015; 53:457-63. https://doi.org/10.3109/13880209.2014.918157.

[152] Li T, Huang J, Zeng A, Yu N, Long X. Ubiquitin-specific peptidase 11 promotes development of keloid derived fibroblasts by de-ubiquitinating TGF-β receptorII. Burns 2024; 50:641-52. https://doi.org/10.1016/j.burns.2023.09.022.

[153] Jin R, Deng Z, Liu F, Lu L, Ding F, Shen Y, et al. Knockdown of ZEB1 inhibits hypertrophic scarring through suppressing the Wnt/β-catenin signaling pathway in a mouse model. Plast Reconstr Surg 2024; 154:991-1001. https://doi.org/10.1097/PRS.0000000000011190.

[154] Gu S, Huang X, Xu X, Liu Y, Khoong Y, Zhang Z, et al. Inhibition of CUB and sushi multiple domains 1 (CSMD1) expression by miRNA-190a-3p enhances hypertrophic scar-derived fibroblast migration in vitro. BMC Genomics 2021; 22:613. https://doi.org/10.1186/s12864-021-07920-8.

[155] Wang Q, Wang P, Qin Z, Yang X, Pan B, Nie F, et al. Altered glucose metabolism and cell function in keloid fibroblasts under hypoxia. Redox Biol 2021; 38:101815. https://doi.org/10.1016/j.redox.2020.101815.

[156] Wang Q, Yang X, Ma J, Xie X, Sun Y, Chang X, et al. PI3K/AKT pathway promotes keloid fibroblasts proliferation by enhancing glycolysis under hypoxia. Wound Repair Regen 2023; 31:139-55. https://doi.org/10.1111/wrr.13067.

[157] Yu B, Cao Y, Lin P, Zhang L, Chen M. Enhancement of Ndrg2 promotes hypertrophic scar fibrosis by regulating PI3K/AKT signaling pathway. Cell Signal 2025; 129:111659. https://doi.org/10.1016/j.cellsig.2025.111659.

[158] Chen H, Xu K, Sun C, Gui S, Wu J, Wang S. Inhibition of ANGPT2 activates autophagy during hypertrophic scar formation via PI3K/AKT/mTOR pathway. An Bras Dermatol 2023; 98:26-35. https://doi.org/10.1016/j.abd.2021.12.005.

[159] Fang S, Wang Z, Xu J, Xu M, Zhou J, Zhang Y, et al. USP37-stabilized SALL4 promotes the keloid formation by PI3K/AKT pathway. Sci Rep 2025; 15:7553. https://doi.org/10.1038/s41598-025-91776-5.

[160] Yang E, Xu R, Tu L, Zhang H, Luo S, Liang H, et al. Single cell deciphering of pruritic keloids: the interaction between fibroblasts and Schwann cells through the midkine signaling. Burns Trauma 2025; 13:tkaf057. https://doi.org/10.1093/burnst/tkaf057.

[161] Feng F, Liu M, Pan L, Wu J, Wang C, Yang L, et al. Biomechanical regulatory factors and therapeutic targets in keloid fibrosis. Front Pharmacol 2022; 13:906212. https://doi.org/10.3389/fphar.2022.906212.

[162] Cao G, Ye M, Wang H, Liu Y, Li M. The role of biomechanical forces in the formation and treatment of pathological scars. Clin Cosmet Investig Dermatol 2024; 17:2565-71. https://doi.org/10.2147/CCID.S496253.

[163] Huang C, Ogawa R. Role of inflammasomes in keloids and hypertrophic scars-lessons learned from chronic diabetic wounds and skin fibrosis. Int J Mol Sci 2022; 23:6820. https://doi.org/10.3390/ijms23126820.

[164] Chen Q, Wan S, Duan Y, Yan J, Zhang M. Immune imbalance drives keloid pathogenesis: emerging targets for precision immunotherapy. Adv Wound Care (New Rochelle) 2026:21621918261417702. https://doi.org/10.1007/10_2026_339.

[165] Lin P, Zhang D, Tian J, Lai B, Yang Y, Yan Y, et al. Dermal fibroblasts retain site-specific transcriptomic identity in keloids. J Dermatol Sci 2024; 116:41-9. https://doi.org/10.1016/j.jdermsci.2024.08.002.

[166] Li Z, Zhang C, Zhang Q, Dong Y, Sha X, Jiang M, et al. Identification of a potential bioinformatics-based biomarker in keloids and its correlation with immune infiltration. Eur J Med Res 2023; 28:476. https://doi.org/10.1186/s40001-023-01421-y.

[167] Alkouz Z, Al Suwait A, Zhang L, Alhejairi R, Gahimbare F, Qalalwa M, et al. Fibroblast dynamics in keloid pathogenesis: unraveling cellular crosstalk and novel therapeutic targets. Dermatol Res Pract 2026; 2026:2528205. https://doi.org/10.1155/drp/2528205.

[168] Zhou L, Zhou Q, Zheng C, Wang Z, Rao M. Multimodal ultrasound assessment for monitoring keloid severity and treatment response. Sci Rep 2025; 15:8568. https://doi.org/10.1038/s41598-025-91111-y.

[169] Abrouk M, Gianatasio C, Li Y, Holmes J, Dong J, Quiñonez RL, et al. An atlas of optical coherence tomography (OCT): elucidating in vivo differences of scar types using OCT in order to guide laser treatment parameters. J Clin Aesthet Dermatol 2022; 15:30-9.

[170] Choi Y, Jang HS, Shim J, Yeo E, Kim MH, Noh H, et al. 3D keloid spheroid model: development and application for personalized drug response prediction. Commun Biol 2024; 7:1470. https://doi.org/10.1038/s42003-024-07194-2.

[171] Bitterman D, Patel P, Wang JY, Kabakova M, Zafar K, Lee A, et al. Systematic review of dupilumab safety and efficacy for treatment of keloid scars. Arch Dermatol Res 2024; 316:560. https://doi.org/10.1007/s00403-024-03277-6.

[172] Huang RS, McMullen EP, Metko D, Piguet V. Dupilumab therapy for keloids and hypertrophic scars: a systematic review. J Cutan Med Surg 2025; 29:81-2. https://doi.org/10.1177/12034754241291041.

[173] Guttman-Yassky E, Diaz A, Pavel AB, Tan K, He H, Xu H, et al. Response to ‘lack of efficacy of dupilumab in the treatment of keloid disorder’ by MH Tirgan and J Uitto. J Eur Acad Dermatol Venereol 2022; 36:e122-3. https://doi.org/10.1111/jdv.17699.

[174] Chen JY, Feng QL, Pan HH, Zhu DH, He RL, Deng CC, et al. An open-label, uncontrolled, single-arm clinical trial of tofacitinib, an oral JAK1 and JAK3 kinase inhibitor in Chinese patients with keloid. Dermatology 2023; 239:818-27. https://doi.org/10.1159/000532064.

[175] Caudrelier N, Veillette H. Acne keloidalis nuchae in a patient with atopic dermatitis treated with Janus kinase inhibitor upadacitinib. JAAD Case Rep 2023; 38:70-1. https://doi.org/10.1016/j.jdcr.2023.06.014.

[176] Kim HY, Cho J, Park MK, Min DH, Hwang JG, Won C. A first-in-human phase 1 study to evaluate the safety and tolerability of LEM-S401, a novel siRNA-DegradaBALL drug targeting CTGF in healthy adults. Clin Transl Sci 2025; 18:e70207. https://doi.org/10.1111/cts.70207.

[177] Kilmister EJ, Tan ST. Insights into vascular anomalies, cancer, and fibroproliferative conditions: the role of stem cells and the renin-angiotensin system. Front Surg 2022; 9:868187. https://doi.org/10.3389/fsurg.2022.868187.

[178] Zhou BY, Wang WB, Wu XL, Zhang WJ, Zhou GD, Gao Z, et al. Nintedanib inhibits keloid fibroblast functions by blocking the phosphorylation of multiple kinases and enhancing receptor internalization. Acta Pharmacol Sin 2020; 41:1234-45. https://doi.org/10.1038/s41401-020-0381-y.

[179] Cristodor PL, Nechifor A, Fotea S, Nadasdy T, Bahloul Y, Nicolescu AC, et al. New antifibroblastic medication in dermatology: could nintedanib treat scarring? Int J Gen Med 2022; 15:7169-72. https://doi.org/10.2147/IJGM.S377073.

[180] Sun P, Hu Z, Pan B, Lu X. Targeting of keloid with TRAIL and TRAIL-R2/DR5. J Dermatolog Treat 2021; 32:957-64. https://doi.org/10.1080/09546634.2020.1714541.

[181] Leelawattanachai J, Sittisaksomjai S, Disphanurat W. Comparative effectiveness of 5-fluorouracil dissolving microneedle patch vs. 5-fluorouracil intralesional injection for the treatment of keloid scars: a randomised, single-blinded, split-scar study. Wound Repair Regen 2025; 33:e70078. https://doi.org/10.1111/wrr.70078.

[182] Zhang JL, Zhou JN, Tang C, Li Y, Yao WD, Guo LL, et al. Sustained-release sitagliptin microneedles for scar prevention via fibroblast-to-adipocyte conversion. Small Sci 2025; 5:e202500140. https://doi.org/10.1002/smsc.202500140.

[183] Mbiine R, Kayiira A, Wayengera M, Guyton MI, Kiwanuka N, Alenyo R, et al. Safety and feasibility of autologous adipose-derived stromal vascular fraction in the treatment of keloids: a phase one randomized controlled pilot trial. Am J Stem Cells 2023; 12:23-36.

[184] Wu M, Zhang J, Xiong N, Ma Y, Yong L, Liu H, et al. Exosomes in hypertrophic scars and keloids: mechanisms and therapeutic potentials-a narrative review. J Cosmet Dermatol 2026; 25:e70705. https://doi.org/10.1111/jocd.70705.

[185] Dai S, Xu M, Pang Q, Sun J, Lin X, Chu X, et al. Hypoxia macrophage-derived exosomal miR-26b-5p targeting PTEN promotes the development of keloids. Burns Trauma 2024; 12:tkad036. https://doi.org/10.1093/burnst/tkad036.

[186] Ou X, Chen L, Yu C, Yan T, Huang B, Wang J, et al. Sandwich therapy with radionuclide combined with intralesional injections based on differences in the spatial structure components of keloids. Aesth Plast Surg 2025; 49:1770-83. https://doi.org/10.1007/s00266-024-04442-y.

[187] Truong K, Prasidha I, Wain T. A systematic review of randomised controlled trials investigating laser assisted drug delivery for the treatment of keloid and hypertrophic scars. Lasers Med Sci 2022; 37:47-59. https://doi.org/10.1007/s10103-021-03296-z.

[188] Tawaranurak N, Pliensiri P, Tawaranurak K. Combination of fractional carbon dioxide laser and topical triamcinolone vs intralesional triamcinolone for keloid treatment: a randomised clinical trial. Int Wound J 2022; 19:1729-35. https://doi.org/10.1111/iwj.13775.

[189] Shilova M, Plummer K, Ware R, Kimble R, Clark J, Cho E, et al. Laser-assisted drug delivery for hypertrophic scar treatment: a scoping review. J Burn Care Res 2026; 47:130-46. https://doi.org/10.1093/jbcr/iraf167.

[190] Haq M, Koza E, Ma MS, Ahmed A, Shi VJ, Cahn B, et al. Acne scarring: protocol for development of a core outcome set for clinical trials. BMJ Open 2025; 15:e088049. https://doi.org/10.1136/bmjopen-2024-088049.

[191] Han P, Zhang J, Ma Y. Uncovering and validating biomarkers associated with RNA methylation modifications in keloids: insights from transcriptomic and mendelian randomization analyses. Burns 2026; 52:107788. https://doi.org/10.1016/j.burns.2025.107788.

[192] Taylor B, Shah A, Bielczyk-Maczyńska E. TGF-β is insufficient to induce adipocyte state loss without concurrent PPARγ downregulation. Sci Rep 2020; 10:14084. https://doi.org/10.1038/s41598-020-71100-z.

[193] Luan W, Fan S, Jiang D, Yang J, He L. Integrated analysis of multi-omics and mendelian randomization identified the role of the IGF1 signaling pathway in keloid. Curr Med Chem 2026. https://doi.org/10.2174/0109298673364800251017115129.